Anti-α4β7 therapeutic antibody (Pre-made Abrilumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Abrilumab (INN; development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.This drug was developed by MedImmune.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-005-1mg	1mg	3090
GMP-Bios-ab-005-10mg	10mg	21890
GMP-Bios-ab-005-100mg	100mg	148000
GMP-Bios-ab-005-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-α4β7 therapeutic antibody (Pre-made Abrilumab biosimilar,Whole mAb)
INN Name	Abrilumab
Target	α4β7
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	Amgen;AstraZeneca
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Crohn's disease;Ulcerative colitis
Development Tech	na